Ulcerative Colitis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 421 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2016, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 14, 28, 20, 1, 1, 45, 12 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively for Ulcerative Colitis.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 7
Ulcerative Colitis Overview 8
Therapeutics Development 9
Ulcerative Colitis - Therapeutics under Development by Companies 11
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 18
Ulcerative Colitis - Pipeline Products Glance 19
Ulcerative Colitis - Products under Development by Companies 23
Ulcerative Colitis - Products under Investigation by Universities/Institutes 32
Ulcerative Colitis - Companies Involved in Therapeutics Development 33
Ulcerative Colitis - Therapeutics Assessment 109
Drug Profiles 123
Ulcerative Colitis - Dormant Projects 379
Ulcerative Colitis - Discontinued Products 389
Ulcerative Colitis - Product Development Milestones 391
Appendix 405

List of Tables

Number of Products under Development for Ulcerative Colitis, H2 2016 24
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2016 25
Number of Products under Development by Companies, H2 2016 27
Number of Products under Development by Companies, H2 2016 (Contd..1) 28
Number of Products under Development by Companies, H2 2016 (Contd..2) 29
Number of Products under Development by Companies, H2 2016 (Contd..3) 30
Number of Products under Development by Companies, H2 2016 (Contd..4) 31
Number of Products under Development by Companies, H2 2016 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H2 2016 33
Comparative Analysis by Late Stage Development, H2 2016 34
Comparative Analysis by Clinical Stage Development, H2 2016 35
Comparative Analysis by Early Stage Development, H2 2016 36
Comparative Analysis by Unknown Stage Development, H2 2016 37
Products under Development by Companies, H2 2016 38
Products under Development by Companies, H2 2016 (Contd..1) 39
Products under Development by Companies, H2 2016 (Contd..2) 40
Products under Development by Companies, H2 2016 (Contd..3) 41
Products under Development by Companies, H2 2016 (Contd..4) 42
Products under Development by Companies, H2 2016 (Contd..5) 43
Products under Development by Companies, H2 2016 (Contd..6) 44
Products under Development by Companies, H2 2016 (Contd..7) 45
Products under Development by Companies, H2 2016 (Contd..8) 46
Products under Investigation by Universities/Institutes, H2 2016 47
Ulcerative Colitis - Pipeline by 4D Pharma Plc, H2 2016 48
Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2016 49
Ulcerative Colitis - Pipeline by Abivax S.A., H2 2016 50
Ulcerative Colitis - Pipeline by Advinus Therapeutics Ltd, H2 2016 51
Ulcerative Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2016 52
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H2 2016 53
Ulcerative Colitis - Pipeline by Amgen Inc., H2 2016 54
Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H2 2016 55
Ulcerative Colitis - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 56
Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2016 57
Ulcerative Colitis - Pipeline by Bionovis SA, H2 2016 58
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2016 59
Ulcerative Colitis - Pipeline by Celgene Corporation, H2 2016 60
Ulcerative Colitis - Pipeline by Cellceutix Corporation, H2 2016 61
Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H2 2016 62
Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2016 63
Ulcerative Colitis - Pipeline by Coherus BioSciences, Inc., H2 2016 64
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2016 65
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 66
Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H2 2016 67
Ulcerative Colitis - Pipeline by Eli Lilly and Company, H2 2016 68
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 69
Ulcerative Colitis - Pipeline by enGene, Inc, H2 2016 70
Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2016 71
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 72
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H2 2016 73
Ulcerative Colitis - Pipeline by Galapagos NV, H2 2016 74
Ulcerative Colitis - Pipeline by Genentech, Inc., H2 2016 75
Ulcerative Colitis - Pipeline by Genor BioPharma Co Ltd, H2 2016 76
Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H2 2016 77
Ulcerative Colitis - Pipeline by GW Pharmaceuticals Plc, H2 2016 78
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H2 2016 79
Ulcerative Colitis - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 80
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H2 2016 81
Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016 82
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H2 2016 83
Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 84
Ulcerative Colitis - Pipeline by Johnson & Johnson, H2 2016 85
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 86
Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 87
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H2 2016 88
Ulcerative Colitis - Pipeline by Lycera Corp., H2 2016 89
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H2 2016 90
Ulcerative Colitis - Pipeline by Merck & Co., Inc., H2 2016 91
Ulcerative Colitis - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016 92
Ulcerative Colitis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 93
Ulcerative Colitis - Pipeline by Morphotek, Inc., H2 2016 94
Ulcerative Colitis - Pipeline by Mycenax Biotech Inc., H2 2016 95
Ulcerative Colitis - Pipeline by NeuClone Pty Ltd, H2 2016 96
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H2 2016 97
Ulcerative Colitis - Pipeline by OSE Immunotherapeutics, H2 2016 98
Ulcerative Colitis - Pipeline by Pfizer Inc., H2 2016 99
Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H2 2016 100
Ulcerative Colitis - Pipeline by ProtAb Ltd, H2 2016 101
Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc., H2 2016 102
Ulcerative Colitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 103
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H2 2016 104
Ulcerative Colitis - Pipeline by Re-Pharm Limited, H2 2016 105
Ulcerative Colitis - Pipeline by Rebiotix Inc., H2 2016 106
Ulcerative Colitis - Pipeline by Sandoz International GmbH, H2 2016 107
Ulcerative Colitis - Pipeline by Seres Therapeutics, Inc., H2 2016 108
Ulcerative Colitis - Pipeline by Shire Plc, H2 2016 109
Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H2 2016 110
Ulcerative Colitis - Pipeline by Stelic Institute & Co., Inc., H2 2016 111
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 112
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016 113
Ulcerative Colitis - Pipeline by Synlogic Inc, H2 2016 114
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 115
Ulcerative Colitis - Pipeline by Therapeutic Proteins International, LLC, H2 2016 116
Ulcerative Colitis - Pipeline by Therapix Biosciences Ltd., H2 2016 117
Ulcerative Colitis - Pipeline by Theravance Biopharma, Inc., H2 2016 118
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H2 2016 119
Ulcerative Colitis - Pipeline by TopiVert Ltd, H2 2016 120
Ulcerative Colitis - Pipeline by Trino Therapeutics Limited, H2 2016 121
Ulcerative Colitis - Pipeline by UCB S.A., H2 2016 122
Ulcerative Colitis - Pipeline by Ventria Bioscience, H2 2016 123
Assessment by Monotherapy Products, H2 2016 124
Number of Products by Stage and Target, H2 2016 126
Number of Products by Stage and Mechanism of Action, H2 2016 130
Number of Products by Stage and Route of Administration, H2 2016 135
Number of Products by Stage and Molecule Type, H2 2016 137
Ulcerative Colitis - Dormant Projects, H2 2016 394
Ulcerative Colitis - Dormant Projects (Contd..1), H2 2016 395
Ulcerative Colitis - Dormant Projects (Contd..2), H2 2016 396
Ulcerative Colitis - Dormant Projects (Contd..3), H2 2016 397
Ulcerative Colitis - Dormant Projects (Contd..4), H2 2016 398
Ulcerative Colitis - Dormant Projects (Contd..5), H2 2016 399
Ulcerative Colitis - Dormant Projects (Contd..6), H2 2016 400
Ulcerative Colitis - Dormant Projects (Contd..7), H2 2016 401
Ulcerative Colitis - Dormant Projects (Contd..8), H2 2016 402
Ulcerative Colitis - Dormant Projects (Contd..9), H2 2016 403
Ulcerative Colitis - Discontinued Products, H2 2016 404
Ulcerative Colitis - Discontinued Products (Contd..1), H2 2016 405